NVCR Latest Headlines

NVCR TRIDENT Trial Shows Durable Survival Rates in Glioblastoma—No Statistically Significant Improvement with Early TTFields Initiation

Market Chameleon (Thu, 18-Jun 7:30 AM)

Analyst Maintains Buy on NovoCure, Trims Price Target to $46 Amid Shift to New Indications and Stable GBM Franchise

at www.tipranks.com (Thu, 18-Jun 11:15 AM)

Novocure falls after late-stage trial setback for cancer treatment device

at seekingalpha.com (Thu, 18-Jun 7:51 AM)

NovoCure Reports Phase 3 TRIDENT Trial Topline Results

at www.tipranks.com (Thu, 18-Jun 7:48 AM)

Novocure Revenue Grows 12% on Global Patient Expansion; New Device Approvals Mark Milestone Quarter

Market Chameleon (Thu, 30-Apr 11:06 AM)

Novocure Delivers 12% Revenue Growth in Q1 2026 as Patient Demand for Optune Devices Surges

Market Chameleon (Thu, 30-Apr 8:24 AM)

Novocure’s TTFields Therapy Achieves 74.4% Disease Control Rate in Metastatic Pancreatic Cancer—Phase 2 PANOVA-4 Results Impress

Market Chameleon (Thu, 26-Mar 9:19 AM)